Mallinckrodt plc Ordinary Shares (MNK) News

Mallinckrodt plc Ordinary Shares (MNK)

Today's Latest Price: $0.93 USD

0.08 (9.41%)

Updated Sep 29 7:00pm

Add MNK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter MNK News Items

MNK News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest MNK News From Around the Web

Below are the latest news stories about Mallinckrodt plc that investors may wish to consider to help them evaluate MNK as an investment opportunity.

Mallinckrodt preparing bankruptcy filing as heavy bills come due - WSJ

Mallinckrodt (MNK +1.8%) is readying a bankruptcy filing within weeks, the WSJ reports, saying it may set up a battle over the company's role in the opioid crisis. The company is talking with key creditors over a restructuring plan covering more than $5B in debt, according to the report -...

Seeking Alpha | September 25, 2020

Mallinckrodt: A Series Of Unfortunate Events

Mallinckrodt (MNK) seems to be a protagonist in the famous series, A Series Of Unfortunate Events. The company has faced multiple black swan events that are out of its control, with the latest being a complete response letter ("CRL") for Terlipressin. But a CRL is the least of its problem....

Zheng Feng Chee on Seeking Alpha | September 22, 2020

Nestle Acquiring Aimmune, And Other News: The Good, Bad And Ugly Of Biopharma

Aimmune to be acquired by Nestle for $2.6 billion Aimmune Therapeutics Inc. (AIMT) announced that it has agreed to be acquired by Nestle Health Science. The acquisition price has been set at $34.50 per share, and the all-cash transaction is expected to be worth $2.6 billion. Nestle will carry out...

Avisol Capital Partners on Seeking Alpha | September 21, 2020

Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Yahoo | September 15, 2020

Mallinckrodt down 11% on FDA rejection of terlipressin for type of kidney failure

The FDA has issued a Complete Response Letter ((CRL)) regarding Mallinckrodt's (MNK) New Drug Application ((NDA)) seeking approval for the investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1), a life-threatening syndrome involving acute kidney failure in people with cirrhosis. The CRL stated that, based on the...

Seeking Alpha | September 14, 2020

A Look Into Mallinckrodt's Debt

Over the past three months, shares of Mallinckrodt (NYSE: MNK) decreased by 54.00%. Before having a look at the importance of debt, let us look at how much debt Mallinckrodt has.Mallinckrodt's Debt Based on Mallinckrodt's balance sheet as of August 4, 2020, long-term debt is at $5.22 billion and current debt is at $86.70 million, amounting to $5.31 billion in total debt. Adjusted for $818.30 million in cash-equivalents, the company's net debt is at $4.49 billion.Shareholders look at the debt-ratio to understand how much financial leverage a company has. Mallinckrodt has $9.69 billion in total assets, therefore making the debt-ratio 0.55. As a rule of thumb, a debt-ratio more than one indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can a...

Yahoo | September 14, 2020

Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) seeking approval for the investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1).

Yahoo | September 14, 2020

The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations

After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference...

Benzinga | September 6, 2020

Mallinckrodt Is Just Too Complex For My Liking

Mallinckrodt PLC (MNK) has an upcoming PDUFA action date on 09/12/2020 for Terlipressin indicated for Hepatorenal syndrome type 1 (HRS-1). However, the stock is still trading pretty low. So, what's going wrong here? For one, the U.S. FDA Advisory Committee for Cardiovascular and Renal Drugs vote in mid-July 2020 was...

Avisol Capital Partners on Seeking Alpha | September 3, 2020

Coalition to Bill Barr: Imprison pharma executives for their roles in opioid crisis

A letter addressed to Attorney General Bill Barr and the U.S. Department of Justice is calling out major pharmaceutical companies for their role in the U.S. opioid crisis. 

Yahoo | August 31, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5965 seconds.